| Autor: |
Thyssen, J. P., Silverberg, J. I., Ruano, J., Blauvelt, A., Gubelin, W., Simpson, E. L., Weidinger, S., Valdez, H., Terry, K. K., Biswas, P., Güler, E., Feeney, C. |
| Předmět: |
|
| Zdroj: |
Journal of the European Academy of Dermatology & Venereology; Nov2024, Vol. 38 Issue 11, p2130-2138, 9p |
| Abstrakt: |
Background: Treatment optimization may require dosing flexibility. The Phase 3 JADE REGIMEN trial (NCT03627767) evaluated maintenance of abrocitinib 200 mg‐induced response in patients with moderate‐to‐severe atopic dermatitis (AD) randomly assigned to subsequent maintenance with continuous‐dose abrocitinib (200 mg), reduced‐dose abrocitinib (100 mg) or placebo. Maintenance with continuous‐dose abrocitinib was associated with a stronger prevention of disease flares, but also with a higher occurrence of adverse events, compared with the reduced dose. Objective: This post hoc analysis of JADE REGIMEN aimed to identify predictors of not flaring during the maintenance period and to generate tools that can be used to assess probability of not flaring. Methods: Data were analysed from patients who responded to abrocitinib 200 mg induction therapy (12 weeks) and were randomly assigned to receive abrocitinib (200 mg or 100 mg) or placebo in the 40‐week maintenance period. Demographic and baseline disease characteristics and level of response to induction were evaluated for association with not flaring using logistic regression. Parameters with a significant (p < 0.15) interaction with the treatment arm were fitted into a multivariable regression model, which was used to assess probability of not flaring. Results: Lower percentage body surface area affected at baseline (p = 0.09), absence of prior exposure to systemic agents (p = 0.02) and greater percentage change in EASI from baseline to randomization (p < 0.001) were identified as predictors of not flaring with abrocitinib. In both abrocitinib arms, percentage change in EASI from baseline to end of induction (Week 12) was the major contributor to the probability of not flaring in the maintenance period. Conclusions: Maintenance of response using reduced‐dose abrocitinib 100 mg may be feasible for patients with lower baseline disease severity and strong response to abrocitinib 200 mg induction treatment. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text